Andrew Fein analyst HC WAINWRIGHT

Currently out of the existing stock ratings of Andrew Fein, 13 are a HOLD (4.69%), 264 are a BUY (95.31%).

Andrew Fein

Work Performance Price Targets & Ratings Chart

Analyst Andrew Fein works at HC WAINWRIGHT with a stock forecast success ratio of 25.14% fulfilled within 85.56 days on average. Previously, Andrew Fein worked at CHARDAN CAPITAL.

Andrew Fein’s has documented 540 price targets and ratings displayed on 55 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ARVN, Arvinas at 29-Feb-2024.

Wall Street Analyst Andrew Fein

Analyst best performing recommendations are on CRBP (CORBUS PHARMACEUTICALS).
The best stock recommendation documented was for AMRN (AMARIN PLC) at 9/25/2018. The price target of $20 was fulfilled within 9 days with a profit of $7 (53.85%) receiving and performance score of 59.83.

Average potential price target upside

ACAD ACADIA Pharmaceuticals ANNX Annexon  BIIB Biogen BLU BELLUS Health . BPMC Blueprint Medicines Corp CRTX Cortexyme DBVT DBV Technologies ELOX Eloxx Pharmaceuticals EPZM Epizyme FHTX Foghorn Therapeutics  IMAB I-Mab MRUS Merus BV OCUP Ocuphire Pharma PRQR ProQR Therapeutics BV SGEN Seagen AMLX Amylyx Pharmaceuticals DCPH Deciphera Pharmaceuticals LLC GMTX Gemini Therapeutics RUBY Rubius Therapeutics TARA Protara Therapeutics UTHR United Therapeutics AMRN Amarin PLC SYRS Syros Pharmaceuticals ZNTL Zentalis Pharmaceuticals Llc CPRX Catalyst Pharmaceuticals CCCC C4 Therapeutics  ARVN Arvinas LQDA Liquidia Technologies ABOS Acumen Pharmaceuticals ACIU AC Immune Ltd CRBP Corbus Pharmaceuticals DNLI Denali Therapeutics FULC Fulcrum Therapeutics KALV Kalvista Pharmaceuticals MEIP MEI Pharma NBIX Neurocrine Biosciences PEPG PepGen Ltd PRTA Prothena plc PULM Pulmatrix STOK Stoke Therapeutics STRO Sutro Biopharma TCRX Tscan Therapeutics THRX Theseus Pharmaceuticals UBX Unity Biotechnology VIGL Vigil Neuroscience VRTX Vertex Pharmaceuticals WVE Wave Life Sciences Ltd ALEC Alector BCRX BioCryst Pharmaceuticals INSM Insmed KMDA Kamada KROS Keros Therapeutics  KYMR Kymera Therapeutics SVRA Savara APRE Aprea Therapeutics

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

42

$15.64 (59.33%)

42

2 days ago

25/33 (75.76%)

$15.64 (59.33%)

486

Buy

39

$12.64 (47.95%)

40

2 days ago

5/10 (50%)

$12.64 (47.95%)

58

Buy

33

$6.64 (25.19%)

33

2 days ago

8/19 (42.11%)

$6.64 (25.19%)

119

Buy

36

$9.64 (36.57%)

2 days ago

0/1 (0%)

$9.64 (36.57%)

Buy

35

$8.64 (32.78%)

33

2 days ago

10/16 (62.5%)

$8.64 (32.78%)

235

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Andrew Fein is most bullish on?

Potential upside of $107.99 has been obtained for BIIB (BIOGEN)

Which stock is Andrew Fein is most reserved on?

Potential downside of -$12.7 has been obtained for KYMR (KYMERA THERAPEUTICS)

What Year was the first public recommendation made by Andrew Fein?

On 2013

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?